POINT Biopharma Global Analysis
PNTDelisted Stock | USD 9.06 0.10 1.09% |
POINT Biopharma Global is overvalued with Real Value of 7.76 and Hype Value of 9.06. The main objective of POINT Biopharma delisted stock analysis is to determine its intrinsic value, which is an estimate of what POINT Biopharma Global is worth, separate from its market price. There are two main types of POINT Biopharma's stock analysis: fundamental analysis and technical analysis.
The POINT Biopharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. POINT Biopharma is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. POINT Stock trading window is adjusted to America/New York timezone.
POINT |
POINT Stock Analysis Notes
About 15.0% of the company outstanding shares are owned by corporate insiders. The book value of POINT Biopharma was at this time reported as 4.01. The company had not issued any dividends in recent years. POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana. Point Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. To find out more about POINT Biopharma Global contact Joe McCann at 647 812 2417 or learn more at https://www.pointbiopharma.com.POINT Biopharma Global Investment Alerts
POINT Biopharma is not yet fully synchronised with the market data | |
POINT Biopharma has a very high chance of going through financial distress in the upcoming years | |
About 15.0% of the company outstanding shares are owned by corporate insiders |
POINT Biopharma Global Upcoming and Recent Events
25th of March 2024 Upcoming Quarterly Report | View | |
20th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
25th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
POINT Market Capitalization
The company currently falls under 'Mid-Cap' category with a total capitalization of 1.33 B.POINT Profitablity
The company has Net Profit Margin of 0.4 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of (10.62) %, which entails that for every $100 of revenue, it lost $10.62.POINT Biopharma Global Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific POINT Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on POINT Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases POINT Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bvf Partners L P over six months ago Sale by Bvf Partners L P of 8974245 shares of POINT Biopharma | ||
Joe McCann over a year ago POINT Biopharma exotic insider transaction detected | ||
Bvf Partners L P over a year ago POINT Biopharma exotic insider transaction detected | ||
Fleshner Neil E over a year ago Bona fide gift to Fleshner Neil E of 250000 shares of POINT Biopharma subject to Section 16 | ||
Martell Bridget A over a year ago Acquisition by Martell Bridget A of 80503 shares of POINT Biopharma subject to Rule 16b-3 | ||
Goodman Jonathan R over a year ago Acquisition by Goodman Jonathan R of 44749 shares of POINT Biopharma subject to Rule 16b-3 | ||
Demers William L over a year ago Acquisition by Demers William L of 131355 shares of POINT Biopharma subject to Rule 16b-3 | ||
Hogue Gerald L over a year ago Exercise or conversion by Hogue Gerald L of 17936 shares of POINT Biopharma subject to Rule 16b-3 |
About POINT Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how POINT Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling POINT shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as POINT Biopharma. By using and applying POINT Stock analysis, traders can create a robust methodology for identifying POINT entry and exit points for their positions.
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana. Point Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding POINT Biopharma to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Companies Directory Now
Companies DirectoryEvaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
All Next | Launch Module |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in POINT Stock
If you are still planning to invest in POINT Biopharma Global check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the POINT Biopharma's history and understand the potential risks before investing.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |